Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity

International Journal of Gynecological Pathology

Volumn 15, Issue 3, 1996, Pages 202-208

  Yamauchi, Naoko ^a,b   Sakamoto, Atsuhiko ^a   Uozaki, Hiroshi ^a   Iihara, Kuniko ^a   Machinami, Rikuo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

bcl 2; Endometrial carcinoma; Histological grading; Immunohistochemistry; p53; Sex steroid receptor

Indexed keywords

ESTROGEN RECEPTOR; GENE PRODUCT; MONOCLONAL ANTIBODY KI 67; PROGESTERONE RECEPTOR; PROTEIN P53; STEROID RECEPTOR;

ADENOCARCINOMA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; ENDOMETRIUM CARCINOMA; FEMALE; GYNECOLOGIC CANCER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; UTERUS CARCINOMA;

EID: 0029948123     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-199607000-00003     Document Type: Article

References (34)

1. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-17.
2. Deligdish L, Cohen C. Histologic correlates and virulence implications of endometrial carcinoma associated with adenomatous hyperplasia. Cancer 1985;56:1452-5.
3. Kurman RJ, Norris HJ. Endometrial carcinoma. In: Kurman RJ, ed. Blaustein's pathology of the female genital tract (4th ed). Berlin: Springer-Verlag, 1994:338.
4. Koshiyama M, Konishi I, Wang DP, et al. Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status. Virch Arch A Pathol Anat 1993;423:265-71.
5. Okamoto A, Sameshima Y, Yamada Y, et al. Alleic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res 1991;51:5632-6.
6. Kohler MF, Berchuck A, Davidoff AM, et al. Over-expression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52:1622-7.
7. Banks L, Matlashewski G, Grawford L, Isolation of human-p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986;159:529-34.
8. Ito K, Watanabe K, Nasim S, et al. Prognostic significance of p53 over-expression in endometrial carcinoma. Cancer Res 1994;54:4667-70.
9. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsp 70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
10. Davidoff AM, Humphrey PA, Iglehart JD, Marks JR, Genetic basis for p53 over-expression in human breast cancer. Proc Natl Acad Sci USA 1991;88:5006-10.
11. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986;47:19-28.
12. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986;83:5214-8.
13. Chen-Levy Z, Nourse J, Cleary ML. The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. Mol Cell Biol 1989;9:701-10.
14. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haematopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440-2.
15. Garcia I, Martinou I, Tsujimoto Y, Martinou JC. Prevention of programmed cell death of sympathetic neurons by the bcl-2 proto-oncogene. Science 1992;258:302-4.
16. Zhong LT, Sarafian T, Kane DJ, et al. Bcl-2 inhibits death of central neural cells induced by multiple agents. Proc Natl Acad Sci USA 1992;90:4533-7.
17. Hockenbery DM, Nuncy G, Millimar C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-6.
18. Jacobson MD, Burne JF, King MP, Miyashita T, Reed JC, Raff MC. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 1993;361:365-9.
19. Lu QL, Poulson R, Wong L, Hanby MA. Bcl-2 expression in adult and embryonic non-hematopoietic tissues. J Pathol 1993;169:431-7.
20. Gompel A, Sabourin JC, Martin A, et al. Bcl-2 expression in normal endometrium during the menstrual cycle. Am J Pathol 1994;144:1195-202.
21. Otsuki Y, Misaki O, Sugimoto O, Ito Y, Tsujimoto Y, Akao Y. Cyclic bcl-2 gene expression in human uterine endometrium during menstrual cycle. Lancet 1994;344:28-9.
22. Deligdish L, Holinka CF. Progesterone receptors in two groups of endometrial carcinoma. Cancer 1986;57:1385-8.
23. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
24. Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-5.
25. Sasaki K, Murakami T, Kawasaki M, Takahashi M. The T cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol 1987;133:579-84.
26. Pickartz H, Beckmann R, Fleige B, Due W, Gerdes J, Stein H. Steroid receptors and proliferative activity in non-neoplastic and neoplastic endometria. Virch Arch A Pathol Anat 1990;417:163-71.
27. Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nucear antigen that's defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867-73.
28. Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies produced against recombinant parts of the Ki-67 molecule (MIB1-3) stain proliferating cells in formalin-fixed, paraffin-embedded, microwave processed tissues [Abstract]. Histochem J 1992;24:611.
29. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. WHO's histological typing of female genital tract tumours. 2nd ed Berlin: Springer-Verlag, 1994.
30. Japan Society of Obstetrics and Gynecology, The Japanese Pathological Society, Japan Radiological Society. The general rules for clinical and pathological management of uterine corpus cancer. Tokyo: Kanahara-Shuppan, 1987.
31. Hermand KP, Sobin LH. TNM classification of malignant tumours. 2nd ed, Berlin: Springer-Verlag, 1987.
32. Gurpide E. Endometrial cancer: biochemical and clinical correlates. J Natl Cancer Inst 1991;83:405-16.
33. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88:6961-5.
34. Gee JM, Robertson JF, Ellis IO, et al. Immunocytochemical localization of Bcl-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 1994;59:619-28.